Staggered launch of new products

Staggered launch of new products

FarmaMondo’s strong and consolidated strategy on a staggered launch as a social responsibility

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with unmet medical needs also in non-launched countries. It may take months or even years before their treatments are approved for commercial supply in certain countries. But patients cannot wait. During this lag time, FarmaMondo responds to global HealthCare Providers’ requests for paid access to medicines, and we supply them via the national unlicensed regulatory route in place. Having a well-sounded and consolidated strategy on a staggered launch is a mandate and social responsibility for research-based pharmaceutical companies. Your partner FarmaMondo can establish a Managed Access Program to capture and serve HealthCare Providers’ named patient requests for paid access in non-launched markets.

farmamondo-unlicensed-medicines-graphic

Contact Us

=

FarmaMondo’s strong and consolidated strategy on a staggered launch as a social responsibility

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with unmet medical needs also in non-launched countries. It may take months or even years before their treatments are approved for commercial supply in certain countries. But patients cannot wait. During this lag time, FarmaMondo responds to global HealthCare Providers’ requests for paid access to medicines, and we supply them via the national unlicensed regulatory route in place. Having a well-sounded and consolidated strategy on a staggered launch is a mandate and social responsibility for research-based pharmaceutical companies. Your partner FarmaMondo can establish a Managed Access Program to capture and serve HealthCare Providers’ named patient requests for paid access in non-launched markets.

farmamondo-unlicensed-medicines-graphic

Contact Us

=

 

HOW WE PROVIDE ACCESS 

Staggered launch of
new products

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with

Shortages of established
products

Medicine shortages are a growing and complex global challenge. Shortages of essential drugs are becoming increasingly frequent globally, burdening health systems with additional costs and posing

Market exit and product
discontinuation

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find

HOW WE PROVIDE ACCESS 

Staggered launch of
new products

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with unmet medical needs also in non-launched countries.

Shortages of established
products

Medicine shortages are a growing and complex global challenge. Shortages of essential drugs are becoming increasingly frequent globally, burdening health systems with additional costs and posing risks to the health of patients who fail to receive the medicines they need.

Market exit and product
discontinuation

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find suitable replacement therapies.

FOLLOW US ON